30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Current & Critical

NASS PREVIEW: A Guide to the Recently-merged in Spine

Who bought whom? A look at mergers and other initiatives that are changing up the names behind the products at this year’s NASS meeting.

Amendia + Baxano + Custom Spine + SpineSelect

Amendia has logged the most acquisitions in the space in 2015, having purchased a piece of Baxano (iO-Flex and iO-Tome assets), all of Custom Spine and its Pathway AVID articulating vertebral interbody device and finally SpineSelect, with its minimally invasive transforaminal lumbar interbody fusion system (MITLIF) and 20 patents.

(Even Amendia’s spin-offs are involved in the M&A scene: in 4Q14, Vivex Biomedical acquired assets and agreements from the University of Miami Tissue Bank, a provider of bone allografts, biomaterial and soft tissue products for applications in spine, orthopaedics, sports medicine, etc.)

Bacterin + X-spine = Xtant Medical

While the two companies maintain separate spaces at NASS, in early 3Q15 Bacterin announced its intent to purchase outstanding common stock of X-spine Systems to create Xtant. X-spine focuses on less-invasive treatments for the degenerative spine, and a majority of procedures using X-spine's portfolio could use an orthobiologic currently offered by Bacterin.

X-spine’s Irix-A™ Lumbar Integrated Fusion System, cleared in 3Q14, will be on display in its booth as a new launch for 2015. The merged entity just announced its first FDA 510(k) clearance, for OsteoSelect® PLUS Demineralized Bone Matrix next-generation putty + demineralized cortical chips. Product launch is slated for 4Q15.

ChoiceSpine + Baxano

Another portion of Baxano was purchased by ChoiceSpine, which picked up the VEO Lateral Access/Interbody Fusion system in 1Q15. VEO received CE Mark approval just this month.
Integra LifeSciences – Spine = SeaSpine

An un-merger, really. This spin-off took all spine-related biologics and fusion hardware, purchased by Integra in 2011, and put it back into an independent publicly-traded company. At its helm is Keith Valentine as Chief Executive Officer, former President and Chief Operating Officer of NuVasive, among other industry veterans.

K2M + KSpine

K2M, itself focused on the treatment of complex spinal disorders, announced its 2Q15 acquisition of KSpine for $0.3 million. Specifically, K2M bought an entire platform of products and IP comprising 19 issued and 45 pending U.S. and ex-U.S. patents addressing motion-preserving scoliosis technology. The company will reportedly consider other acquisitions, partnerships and licensing agreements in imaging, navigation and robotics.

As of 2011, KSpine had raised $16 million which in part supported clinical trials. KSpine’s technology was developed by surgeons Dr. Allen Carl and Dr. Dan Sachs, and was designed to use less hardware and reduce both procedure time and the number of spine segments fused together.

At NASS, expect to see three new products in K2M’s booth: the CASCADIA™ AN Interbody CAPRI™ Corpectomy Cage and NILE™ Alternative Fixation Spinal systems.

You might have noticed another familiar name on the floor: TranS1, back and restructured under the new ownership of Quandary Medical, which purchased AxiaLIF+® interbody fusion technology and the Vectre™ facet fusion system.

New leadership for TranS1 includes a recently-announced Vice President of Sales with experience at Baxano, TranS1, SpineFrontier and Stryker. Members of the new R&D and consulting teams hail from Baxano and TranS1, as well.

Headed to NASS? We'll be there! Visit us in booth 765!